The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
After watching this activity, participants should be better able to:
- Recognize the rationale for mRNA-based vaccines and considerations for their design
- Discuss the effectiveness of mRNA-based vaccines to manage respiratory viral diseases based on clinical and real-world experiences with COVID-19 vaccines
- Discuss recent developments in the use of the mRNA platform to develop prophylactic and therapeutic vaccines for respiratory diseases
Leading experts explore mRNA vaccine platforms for respiratory viruses, including their design, clinical application and future prospects.
This activity is jointly provided by USF Health and touchIME. read more
Infectious disease specialists, pulmonologists, pharmacists, primary care physicians and primary care nurses involved in the delivery of vaccines for respiratory diseases.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Anna Blakney discloses: Advisory board or panel fees from GenVax. Grants/research support from Pfizer and Replicate Bioscience. Contractual service fees from Moderna (Relationship Terminated).
Prof. Dr. med. Oliver Cornely discloses: Grant Research and Support from Amplyx, Basilea, BMBF, Cidara, DZIF, Gilead, Matinas, MedPace, MSD, Mundipharma, Pfizer and Scynexis. Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC and Pfizer. Speaker’s Bureau from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana, Hikma, MedUpdate, Merck/MSD, Mylan, Noscendo and United Medical/Knight. Expert testimony from Cidara. Data Safety Monitoring Board or Advisory Board from Actelion, Cidara, Entasis, IQVIA, Janssen, Med Pace, Paratek, Pulmocide and Shionogi. Other from DZIF – German Center for Infection Research.
Prof. Ann R Falsey discloses: Advisory board or panel fees from Sanofi. Consultancy fees from Gilead. Grants/research support from BioFire Diagnostics, CyanVac, Janssen, Merck, Moderna and Pfizer.
Sally F Alrabaa, MD, has no relevant financial relationships to disclose.
Touch Medical Contributors
Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 21 September 2023. Date credits expire: 21 September 2024.
If you have any questions regarding credit please contact firstname.lastname@example.org.
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Practical considerations for COVID-19 vaccination in the Middle EastThis activity is CE/CME accredited
Michael Ison: Highlights from IDWeek 2022
RECOVERY Trial Data on Baricitinib in Patients Hospitalized with Coronavirus Disease 2019
Evangelos Giamarellos-Bourboulis: Highlights from ECCMID 2022
Promising Antibody Combination Therapy for COVID-19 Treatment: An Alternative to Vaccination in Individuals with Poor Vaccine Immune Response
COVID-19 in clinical practice
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out